Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Collects $32.5M from Aclara on 2001 Settlement

SAN FRANCISCO, Oct. 15 - Caliper Technologies said today it received $32.5 million from Aclara Biosciences as part of a settlement from 2001 litigation.


Caliper will recognize $5 million of the payment as licensee fee revenue and $27.5 million as part of the settlement in its income statement, the company said.


Caliper said it will also receive a minimum of $2.5 million as royalty payments by December 31 of 2002 and 2003 under terms of the settlement.


In 2001, Caliper and Aclara settled lawsuits brought upon Aclara for infringing on lab-on-chip technology and Caliper for infringing on microfluidics methods. Previously, a jury granted Caliper $52 million in damages against Aclara for misappropriating its trade secrets, though this amount was reduced by a judge to $35 million.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.